Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elanco Animal Health Incorporated Common Stock (NY:ELAN)

11.96 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elanco Animal Health Incorporated Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Elanco (ELAN) Stock Trades Up, Here Is Why
Shares of animal health company Elanco (NYSE:ELAN) jumped 21.2% in the afternoon session after the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
Elanco beat Q1 expectations with adjusted EPS of $0.37 and raised its 2025 revenue forecast, citing strong demand and favorable currency trends. 
Via Benzinga
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
What Does the Market Think About Elanco Animal Health?
Via Benzinga
Is the Market Bullish or Bearish on Elanco Animal Health?
Via Benzinga
Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue... 
Via StockStory
Elanco (ELAN) Reports Q1: Everything You Need To Know Ahead Of Earnings
Animal health company Elanco (NYSE:ELAN) will be reporting results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Elanco Animal Health Stock
Via Benzinga
(ELAN) - Analyzing Elanco Animal Health's Short Interest
Via Benzinga
ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Volatile Stocks with Questionable Fundamentals
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
3 Profitable Stocks Walking a Fine Line
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
3 Value Stocks in the Doghouse
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Peering Into Elanco Animal Health's Recent Short Interest
Via Benzinga
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
1 Small-Cap Stock to Target This Week and 2 to Turn Down
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
3 Reasons to Sell ELAN and 1 Stock to Buy Instead
Elanco has gotten torched over the last six months - since September 2024, its stock price has dropped 28.5% to $10.39 per share. This was partly due to its softer quarterly results and might have... 
Via StockStory
3 Stocks Under $50 in Hot Water
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Tesla To $370? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Elanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff
Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge. 
Via Benzinga
Elanco Animal Health (ELAN) Q4 2024 Earnings Call Transcript
ELAN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Elanco (NYSE:ELAN) Surprises With Q4 Sales
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.4% year on year to $1.02 billion. On the other hand, the company’s... 
Via StockStory
Elanco (ELAN) Q4 Earnings Report Preview: What To Look For
Animal health company Elanco (NYSE:ELAN) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Jim Cramer: AMD Is A 'Great' Company, Hold Onto Dow Inc.
Cramer says people believe AMD "will not be able to deliver on this quarter" and so he's reluctant to get in. 
Via Benzinga
Topics Stocks
Exposures US Equities
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.